Role of anti-ischemic drugs not affecting hemodynamics and / or heart rate in the treatment of patients with ischemic heart disease: Evidence-based rationales for the use
The review presents evidence-based data demonstrating efficacy of trimetazidine and ranolazine, the drugs not affecting hemodynamics and/or heart rate, for treatment of patients with stable IHD. Despite the absence of strict proofs for a beneficial effect of such drugs on the prognosis, results of meta-analyses have suggested that the trimetazidine treatment is associated with a trend to reduced mortality of patients with CHF and decreased LV EF. Good tolerability and safety have been shown for both drugs.